Guardant reported 36% revenue growth in the quarter and 83,000 Shield colorectal cancer screening tests, which is a 26% sequential increase. Management bumped full-year guidance for revenue up to $1.36 billion-$1.37 billion, or 1% higher than the guidance given in July at the midpoints.
Guardant is a leader in liquid biopsy, has been a step ahead of the competition, and is making steady progress toward profitability around 2028.
Guardant’s Shield could face stiff competition if multicancer early-detection tests eventually achieve comparable sensitivity and pricing.
Metric | GH | ILMN |
|---|---|---|
Price/Earnings (Normalized) | — | 38.63 |
Price/Book Value | — | 10.00 |
Price/Sales | 15.65 | 7.01 |
Price/Cash Flow | — | 24.04 |
Metric | GH | ILMN |
|---|---|---|
Quick Ratio | 3.25 | 1.79 |
Current Ratio | 3.60 | 2.63 |
Interest Coverage | −100.00 | 11.48 |
Metric | GH | ILMN |
|---|---|---|
Return on Assets (Normalized) | −12.08% | 15.38% |
Return on Equity (Normalized) | — | 36.69% |
Return on Invested Capital (Normalized) | −18.10% | 20.12% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|%?f?@#>! | LOCK|HCm | $259B | |||
| Danaher Corp DHR | LOCK|!J>#Gsn$ | LOCK|%@ | $164B | |||
| IDEXX Laboratories Inc IDXX | LOCK|^Gj&BRVw | LOCK|^V | $55B | |||
| Agilent Technologies Inc A | LOCK|&?rvlJn^ | LOCK|&v | $49B | |||
| Waters Corp WAT | LOCK|D^b^T!C | LOCK|%! | $45B | |||
| IQVIA Holdings Inc IQV | LOCK|b#WkFq | LOCK|GNw%^ | $44B | |||
| Mettler-Toledo International Inc MTD | LOCK|wjVK^szB | LOCK|b<^GP | $35B | |||
| Illumina Inc ILMN | LOCK|V<$G%Yq | LOCK|WX@jx | $31B | |||
| Labcorp Holdings Inc LH | LOCK|PtKM!bXm | LOCK|&!yLB | $30B | |||
| Quest Diagnostics Inc DGX | LOCK|Ht%bfN | LOCK|pgY$S | $29B |
United States